How does Boston Scientific (BSX) make money?

Boston Scientific (BSX) generates revenue primarily from Cardiovascular, which accounted for 66% of total revenue in TTM through Q1 2026. The company reported $20.61B in revenue and converted 17.2% of it into net profit, equivalent to roughly $3.55B in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Boston Scientific (BSX)?

Boston Scientific (BSX) reported a gross profit margin of 70.4% in TTM through Q1 2026, equivalent to $14.52B in gross profit on $20.61B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Boston Scientific (BSX)?

Boston Scientific (BSX) reported an operating profit margin of 20.1% in TTM through Q1 2026, equivalent to $4.15B in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Boston Scientific (BSX)?

Boston Scientific (BSX) reported a net profit margin of 17.2% in TTM through Q1 2026, equivalent to $3.55B in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Boston Scientific (BSX) profitable?

Yes. Boston Scientific (BSX) reported $3.55B in net income for TTM through Q1 2026, with a net profit margin of 17.2%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Boston Scientific (BSX) invest in research and development?

Boston Scientific (BSX) invested $2.13B in research and development during TTM through Q1 2026, roughly 10.3% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Boston Scientific (BSX) spend on capital expenditures?

Boston Scientific (BSX) spent $899.00M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 4.4% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Boston Scientific (BSX) generate?

Boston Scientific (BSX) generated $3.44B in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 16.7%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Boston Scientific (BSX)?

Boston Scientific (BSX) had an effective tax rate of 4.9% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Boston Scientific (BSX)?

Boston Scientific (BSX) reports revenue across 2 reportable product segments, led by Cardiovascular at 66% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

How Boston Scientific Makes Money: 2026 Visual Revenue Map

Boston Scientific (BSX) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported March 31, 2026).

Boston Scientific discloses geographic revenue only in annual filings. to view the full breakdown.

Boston Scientific (BSX) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Boston Scientific (BSX) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Cardiovascular	$13.60B	66%
MedSurg	$7.02B	34%
Total	$20.61B	100%

Cardiovascular$13.60B
MedSurg$7.02B
Total$20.61B

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Boston Scientific (BSX) reports revenue across 2 operating segments; the largest segment was Cardiovascular at 66%, followed by MedSurg (34%).

Frequently asked questions

Data & methodology

Boston Scientific (BSX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

BSX Overview

Counters

Income Statement

Cash Flow

Capital Return

Forecast & Valuation